Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm Phase Ib/II Study of the Combination of Lenvatinib and Eribulin in Advanced Adipocytic Sarcoma and Leiomyosarcoma (LEADER Study)

NCT03526679 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT03526679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03526679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm Phase Ib/II Study of the Combination of Lenvatinib and Eribulin in Advanced Adipocytic Sarcoma and Leiomyosarcoma (LEADER Study)
Lead sponsor
National Taiwan University Hospital
Phase
Phase 1/2
Overall status
Completed
Start date
July 12, 2018
Completion date
October 30, 2025
Enrollment
30 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, leiomyosarcoma, liposarcoma, soft tissue sarcoma adult